Supplemental

Anticoagulants for cancer-associated thrombosis – insights from a Danish Cardio-Oncology center

Supplemental Table 1 Significant drug-drug interactions identified by 2018 European Heart Rhythm Association guidelines and adverse events associated

	2018 European Heart Rhythm Association	Hellfritzsch et al.	N	Adverse events (N)	Type of adverse event
Cabozantinib			1	0	
Crizotinib			1	0	
Dexamethasone			1	0	
Doxorubicin			3	1	Stroke
Imatinib			2	0	
Sunitinib			2	1	Minor bleeding not requiring hospitalization

Adverse events included re-thrombosis, major bleedings, clinically relevant non-major bleedings, minor bleedings and stroke.

Supplemental Figure 1 Flowchart of study population



Flowchart of the study population stratified by the cancer types included in the study. Patients not eligible for DOAC were excluded from the main analysis.

Abbreviations: CNS = Central nervous system, eGFR= estimated glomerular filtration rate, GI = Gastrointestinal

Supplemental Figure 2 Distribution of drug-drug interaction between antineoplastic agents and DOAC classified by the EHRA report and by the Hellfritzsch et al. review in patients receiving active cancer treatment



Panel A is the distribution of drug-drug interactions according to EHRA; Panel B is the distribution of drug-drug interaction according to Hellfritzcsh et al.